CD123 a novel biomaker for diagnosis and treatment of leukemia.

CD123 a novel biomaker for diagnosis and treatment of leukemia. Cardiovasc Hematol Disord Drug Targets. 2019 Jun 26;: Authors: Shi M, Jeanna Su R, Parmar KP, Chaudhry R, Sun K, Rao J, Chen M Abstract Leukemia is a group of progressive hematologic malignancies derived from hematopoietic stem cells (HSCs) in bone marrow which causes a large number of cancer deaths. Even with treatment such as traditional chemotherapy, targeted therapy, and allogeneic stem cell transplantation (allo-HSCT), the majority of patients in the end relapse with drug-resistance and the overall survival is dismal. Leukemic stem cells (LSCs) take responsibility for the evolution, relapse and drug-resistance of leukemia. Emerging studies demonstrate that CD123, or interleukin 3 receptor (IL-3Rα), is highly expressed on LSCs and contributes a unique marker to extract LSCs form HSCs, and relating to treatment response, minimal residual disease (MRD) detection and prognosis. Furthermore, CD123's differential expression on LSCs and normal HSCs makes it a potential targeted therapy candidate for refractory or relapsed leukemia. Anti-CD123 target-therapies in pre-clinical studies and clinical trials that use anti-CD123 antibody-drugs, CD3×CD123 bispecific antibodies, dual-affinity re-targeting (DART), and anti-CD123 chimeric antigen receptor-modified T-cell (CAR-T) therapies are in progress. This review analyzes the studies about CD123 overexpression in leukemia and t...
Source: Cardiovascular and Hematological Disorders Drug Targets - Category: Drugs & Pharmacology Tags: Cardiovasc Hematol Disord Drug Targets Source Type: research